{
    "nctId": "NCT05921253",
    "briefTitle": "Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy",
    "officialTitle": "Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Lymphoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 104,
    "primaryOutcomeMeasure": "Effects of low-level tragus stimulation (LLTS) on global longitudinal strain (GLS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients (\\>50 years) with breast cancer or lymphoma, who have received anthracycline-based therapy (a cumulative dose of \u2265 200 mg/m2 Doxorubicin or bioequivalent dose of other anthracyclines) and/or HER2 antagonists within the last 60-90 days and have \\>= 1 of following additional criteria:\n\n* previous chest radiation,\n* type 2 diabetes mellitus,\n* hypertension,\n* current smoking,\n* obesity (BMI \u2265 30),\n* previous myocardial infarction or\n* established atherosclerotic heart disease.\n\nExclusion Criteria:\n\n1. atrial paced rhythm,\n2. history of seizure currently on treatment,\n3. history of vasovagal syncope,\n4. end stage liver or kidney disease.",
    "sex": "ALL",
    "minimumAge": "50 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}